EUCTR2019-000620-17-SE进行中（未招募）1 期
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Proof of ConceptStudy (section A) with a conditional dose finding follow up (Section B) to Evaluate theEfficacy on Cervical ripening, Safety, Tolerability and dose response of SubcutaneouslyAdministered Tafoxiparin in Term Pregnant, Nulliparous Women with an unripe cervixundergoing Labor Induction.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Dilafor AB
- 入组人数
- 334
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •i)Pregnant women of =18 and = 64 years of age
- •ii) Nulliparous
- •iii) Unripe cervix with = 4points according to
- •Bishop/Westin score (0-10 points scale)
- •iv) Planned for labor induction after 4-7 days of IMP
- •Examples of diagnosis as a basis for induction:
- •Post term pregnancy (40-41 weeks of gestation)
- •Gestational diabetes
- •Diabetes type 1 - well controlled
- •Pre-eclampsia (BP diastolic <100, systolic <140)
- •Hypertension - well controlled
- •Hepatosis (without clinically significantly elevated
- •serum bile acids)
- •Maternal age = 40 years
- •Humanitarian-psycho social reasons
- •Oligohydramnios
- •v) Gestational age > 37 weeks confirmed by ultrasound
- •before 21 weeks of gestation
- •vi) Singleton pregnancy
- •vii) Subject is, as per the discretion of the Investigator,
- •able to comply with the
- •requirements of the protocol including an ability to
- •be present at all required controls
- •viii) Subject can understand and sign an informed form
- •ix) Provision of written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 334
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •i) Subjects who are unable to understand the written and
- •verbal instructions in local language
- •ii) Breech presentation and other abnormal fetal
- •presentations
- •iii) Previous uterine scar
- •iv)Spontaneous rupture of membranes at inclusion
- •v) Pathologic CTG at inclusion
- •vi) Fetal estimated weight > 2SD of normal fetal
- •estimated weight earlier diagnosed by ultrasound and
- •documented in patient record
- •vii) Mother’s BMI > 35 at early pregnancy
- •viii) Known IUGR defined as = 2SD of normal
- •ix) Presence of eclampsia
- •x) Severe Pre-eclampsia
- •xi) HELLP syndrome (hemolysis, elevated liver enzymes,
- •and low platelets)
- •xii) Clinically significant vaginal bleeding in need of
- •hospitalization in the third trimester
- •xiii) Placenta previa
- •xiv) Previously known coagulation disorders (Leiden,
- •heterozygote - OK)
- •xv) Treatment with a heparin/LMWH product during the previous six months
- •xvi) Current use of any drugs that interfere with hemostasis
- •(including heparin /LMWH, oral anti-coagulant
- •medication, non-steroidal anti-inflammatory drugs
- •(NSAID) compounds and vitamin K antagonists.)
- •xvii) Current use of acetylsalicylic acid (ASA) compounds
- •or use within the week preceding inclusion
- •xviii) Diagnosed with HIV or Acute hepatitis
- •xix) Known history of allergy to standard heparin
- •and/or LMWH heparin
- •xx) History of heparin-induced thrombocytopenia
- •xxi) Current drug or alcohol abuse which in the opinion
- •of the Investigator should preclude participation in
- •xxii) Current participation in other interventional medicinal
- •treatment studies
- •xxiii) Subject has a fear of needles which is believed by the
- •Investigator to affect study medication compliance
- •xxiv)Any relevant condition, laboratory value or concomitant medication which, in the opinion of the investigator, makes the subject unsuitable for entry into the study
研究者
相似试验
进行中（未招募）
不适用
Efficacy and Safety of REGN727/SAR236553 Versus Placebo in Patients with Heterozygous Familial Hypercholesterolemia Not Adequately Controlled with Their Lipid-Modifying TherapyEUCTR2012-001222-95-NLRegeneron Pharmaceuticals Inc.250
进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 4 Weeks in Adult and Adolescent Subjects (12 years of age and older) with Vasomotor/Idiopathic RhinitisVasomotor/Idiopathic RhinitisEUCTR2004-004744-43-NOGlaxoSmithKline Research & Development Ltd347
进行中（未招募）
1 期
Baricitinib in Patients with COVID-19 InfectioCOVID-19 infectionMedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-001517-21-DEEli Lilly and Company1,400
进行中（未招募）
1 期
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With AlirocumabMedDRA version: 20.0Level: PTClassification code 10051592Term: Acute coronary syndromeSystem Organ Class: 10007541 - Cardiac disordersAcute coronary syndromeEUCTR2011-005698-21-DEsanofi-aventis Recherche & Développement18,600
进行中（未招募）
1 期
Efficacy and Safety of SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients with Heterozygous Familial HypercholesterolemiaEUCTR2011-005109-56-NLsanofi-aventis Recherche & Développement486